Skip to main content

Table 1 Constitutive expression and decrease of CXCR4 at the surface of human colorectal carcinoma cells due to anticancer drugs

From: Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26

Cell line Basal CXCR4 expression (cpm/105 cells) Drug treatment
   5-FU Cis Vin MTX
   Maximal decrease (% from control)
HT-29 470 ± 52 75 ± 6.1* 72 ± 6.3* 75 ± 12* 56 ± 7.6*
T84 220 ± 53 42 ± 15 48 ± 22 27 ± 4.4 39 ± 21
HRT-18 62 ± 27 59 ± 18 29 ± 11 76 ± 8.4 63 ± 27
SW480 230 ± 41 24 ± 13 32 ± 13 71 ± 7.6* 24 ± 6.4
SW620 80 ± 29 70 ± 7.0 77 ± 13* 72 ± 18 73 ± 3.0
  1. The relative basal cell-surface protein expression for each cell line was summarized from 8–28 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CXCR4 was determined by radioimmunobinding assay 48 h later. Maximal decrease of CXCR4 was recorded from 3–8 independent dose–response experiments for each drug and cell line. Data are shown as mean % decreases ± SE. *, significant % decrease due to drug, P < 0.05 using paired t-test